🇺🇸 FDA
Pipeline program

CM313 Injection

IIT2023068

Phase 2 small_molecule active

Quick answer

CM313 Injection for Immune Thrombocytopenia is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 2 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Immune Thrombocytopenia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials